NeOnc Technologies Holdings, Inc., a clinical-stage life sciences company, focuses on the development and commercialization of central nervous system therapeutics designed to overcome the blood-brain barrier. The company’s NEO drug development platform produces a portfolio of novel drug candidates and delivery methods with patent protections. Its NEO100-01 and NEO100-02 therapeutics are in Phase II, and the NEO100-03 and NEO212 therapeutics are in Phase I clinical trials, advancing under FDA Fast-Track and Investigational New Drug status. NeOnc Technologies Holdings, Inc. was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was founded in 2008 and is based in Westlake Village, California.